Allogene Therapeutics, Inc. - COM (ALLO)

Historical Portfolio Holders from Q1 2016 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / COM
Shares, excl. options Q2 2024
165M
Holdings value Q2 2024
$385M
Value change Q2 2024
+$75.3M
Grand Portfolio weight change Q2 2024
+0%
Number of holders
166
Number of buys Q2 2024
20
Number of sells Q2 2024
-21
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 20.1M $56.5M -$2.9M $2.80 51
2024 Q2 165M $385M +$75.3M $2.33 166
2024 Q1 131M $586M +$47.2M $4.47 154
2023 Q4 122M $390M -$22.1M $3.21 165
2023 Q3 129M $408M -$20.7M $3.17 149
2023 Q2 132M $658M +$77.6M $4.97 166
2023 Q1 117M $577M +$25.7M $4.94 174
2022 Q4 111M $698M +$14.7M $6.29 163
2022 Q3 106M $1.15B +$54.4M $10.80 180
2022 Q2 101M $1.15B +$111M $11.40 154
2022 Q1 91.7M $836M +$16.2M $9.11 172
2021 Q4 85.8M $1.28B -$105M $14.92 167
2021 Q3 86.1M $2.21B +$36.2M $25.70 164
2021 Q2 86.3M $2.25B -$84.5M $26.08 177
2021 Q1 86.5M $3.05B -$11.8M $35.30 169
2020 Q4 87.5M $2.21B +$86.5M $25.24 159
2020 Q3 83.1M $3.13B -$164M $37.71 158
2020 Q2 86.9M $3.72B +$671M $42.82 170
2020 Q1 73.7M $1.39B +$45.7M $19.44 114
2019 Q4 71.6M $1.86B +$73.7M $25.98 115
2019 Q3 68.7M $1.76B +$43.7M $27.26 96
2019 Q2 68.9M $1.69B +$152M $26.85 94
2019 Q1 65.4M $1.66B +$80.5M $28.91 87
2018 Q4 55M $1.47B +$1.47B $26.93 79
2016 Q2 0 $0 -$115K 0
2016 Q1 4.03K $115K $0 $28.51 1